Darexaban

{{Chembox | ImageFile = Darexaban.png | ImageSize = 200px | IUPACName = N-(3-Hydroxy-2-{[4-(4-methyl-1,4-diazepan-1-yl)benzoyl]amino}phenyl)-4-methoxybenzamide | OtherNames = YM150 | Section1 = ! colspan=2 style="background: #f8eaba; text-align: center;" |Identifiers

|-

|

CAS Number

|

• 365462-23-3 ^Y
• 365462-24-4 (maleate) ^Y

|-

|

3D model (JSmol)

|

• Interactive image

|-

| ChemSpider

|

• 8088422

|-

| ECHA InfoCard | |-

|

PubChem CID

|

• 9912771

|-

| colspan="2" |

InChI

• InChI=1S/C27H30N4O4/c1-30-15-4-16-31(18-17-30)21-11-7-19(8-12-21)27(34)29-25-23(5-3-6-24(25)32)28-26(33)20-9-13-22(35-2)14-10-20/h3,5-14,32H,4,15-18H2,1-2H3,(H,28,33)(H,29,34)

  Key: IJNIQYINMSGIPS-UHFFFAOYSA-N
• InChI=1/C27H30N4O4/c1-30-15-4-16-31(18-17-30)21-11-7-19(8-12-21)27(34)29-25-23(5-3-6-24(25)32)28-26(33)20-9-13-22(35-2)14-10-20/h3,5-14,32H,4,15-18H2,1-2H3,(H,28,33)(H,29,34)

  Key: IJNIQYINMSGIPS-UHFFFAOYAJ

|-

| colspan="2" |

SMILES

• O=C(c1ccc(OC)cc1)Nc2cccc(O)c2NC(=O)c4ccc(N3CCCN(C)CC3)cc4

|- | Section2 = ! colspan=2 style="background: #f8eaba; text-align: center;" |Properties

|-

|

Chemical formula

| C₂₇H₃₀N₄O₄

|- | Molar mass

| 474.56 g·mol⁻¹

|- | Section3 = }}

WikiDoc Resources for Darexaban
Articles
Most recent articles on Darexaban Most cited articles on Darexaban Review articles on Darexaban Articles on Darexaban in N Eng J Med, Lancet, BMJ
Media
Powerpoint slides on Darexaban Images of Darexaban Photos of Darexaban Podcasts & MP3s on Darexaban Videos on Darexaban
Evidence Based Medicine
Cochrane Collaboration on Darexaban Bandolier on Darexaban TRIP on Darexaban
Clinical Trials
Ongoing Trials on Darexaban at Clinical Trials.gov Trial results on Darexaban Clinical Trials on Darexaban at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on Darexaban NICE Guidance on Darexaban NHS PRODIGY Guidance FDA on Darexaban CDC on Darexaban
Books
Books on Darexaban
News
Darexaban in the news Be alerted to news on Darexaban News trends on Darexaban
Commentary
Blogs on Darexaban
Definitions
Definitions of Darexaban
Patient Resources / Community
Patient resources on Darexaban Discussion groups on Darexaban Patient Handouts on Darexaban Directions to Hospitals Treating Darexaban Risk calculators and risk factors for Darexaban
Healthcare Provider Resources
Symptoms of Darexaban Causes & Risk Factors for Darexaban Diagnostic studies for Darexaban Treatment of Darexaban
Continuing Medical Education (CME)
CME Programs on Darexaban
International
Darexaban en Espanol Darexaban en Francais
Business
Darexaban in the Marketplace Patents on Darexaban
Experimental / Informatics
List of terms related to Darexaban

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Darexaban (YM150) is a direct inhibitor of factor Xa created by Astellas Pharma. It is an experimental drug that acts as an anticoagulant and antithrombotic to prevent venous thromboembolism after a major orthopaedic surgery, stroke in patients with atrial fibrillation and possibly ischemic events in acute coronary syndrome. It is used in form of the maleate. The development of darexaban was discontinued in September 2011.

Factor Xa

Factor Xa (FXa) is an essential blood coagulation factor that is responsible for the initiation of the coagulation cascade. FXa cleaves prothrombin to its active form thrombin, which then acts to convert soluble fibrinogen to insoluble fibrin and to activate platelets. Stabilization of the platelet aggregation by fibrin mesh ultimately leads to clot formation.

Metabolism

Darexaban is rapidly absorbed and extensively metabolized in the liver to its active metabolite, darexaban glucuronide (YM-222714) during first pass metabolism via glucuronidation. The metabolism of darexaban also occurs in the small intestine but to a much lesser extent. Glucuronidation of darexaban occurs quickly, thus the half life of darexaban itself is short. However, the resultant darexaban glucuronide metabolite has a long half life of approximately 14–18 hours, reaching its maximum levels in the blood 1-1.5 hour post dose. As a result, darexaban glucuronide is the main determinant of the antithrombotic effects. Darexaban shows minimal interaction with food and is excreted through the kidneys (urine) and feces.

Mechanism of action

Darexaban and darexaban glucuronide selectively and competitively inhibit FXa, suppressing prothrombin activity at the sites of blood clot (thrombus) formation. This leads to a decrease in blood clot formation in a dose dependent manner. Reducing blood clot formation will decrease blood flow blockages, thus possibly lowering the risk of myocardial infarction, unstable angina, venous thrombosis, and ischemic stroke.

Clinical uses

Atrial fibrillation

Atrial fibrillation is an abnormal heart rhythm that causes a reduction in the cardiac output and blood flow to the brain. It also promotes the formation of blood clots in the atria. Atrial fibrillation is associated with an increased risk of embolic stroke due to the increased risk of blood clot development. Oral anticoagulant drugs such as Darexaban decrease the incidence and severity of stroke in patients with atrial fibrillation by preventing the formation of blood clots.

Contraindictions

The RUBY-1 phase II trial results show that oral administration of darexaban in combination with the standard dual antiplatelet therapy used for ACS patients caused a two- to four-fold increase in bleeding rates and no effect on ACS. Though there were no cases of fatal bleeding or intracranial haemorrhage, the results of this study questions the concept of adding an oral anticoagulant to standard of care dual antiplatelet therapy in order to prevent recurrent ischemic events after ACS. The developpement of darexaban was discontinued in September 2011.